That's a bummer. Will try to call when I get a chance. Sorry.I missed your prior post.
Some women felt they needed the 2u - one of whom was Amy Tenderich of DiabetesMine. She was aware of the kinetics but still felt 4u was too much for an adjustment. I believe she said she experienced a low with the 4u and felt that she might need to adjust her basal (I think). You can check out her comments on Twitter if you haven't already.
He may have said he didn't care about the money, but he also said that he chose Sanofi because he wanted to ensure that Afrezza reached millions of diabetics.
There appears to be a question about whether Afrezza sales reported by Sanofi reflect inventories as well as actual scripts. Here is an example of how Jazz Pharmaceuticals treated revenue recognition for Xyrem and Luvox sold through distributors in a 10Q filing May 2009. Based on quotes from the 10Q, the revenue recognized does not seem to support the notion that sales include those in inventory at distributors, and assuming these same rules apply to Afrezza , there may be a good chance that the Afrezza numbers do not include inventories. A call to Matt might also clarify this for us.
Xyrem:"Revenues from sales of Xyrem within the United States are recognized upon transfer of title, which occurs when our specialty pharmaceutical distributor, Express Scripts Specialty Distribution Services, Inc., or Express Scripts, removes product from our consigned inventory location at our facility for shipment to a patient."
Luvox: "Luvox CR was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of obsessive compulsive disorder and social anxiety disorder and we shipped initial stocking orders to our wholesaler customers in the first quarter of 2008. Luvox CR is subject to rights of return six months prior to and up to twelve months after product expiration. We are not able to reliably estimate expected returns of Luvox CR at the time of shipment and therefore we have recognized revenue when units were dispensed through prescriptions at which point, we believe, the product is not subject to return. In order to estimate units dispensed, we purchase dispensing data which we believe to be accurate and reliable and not subject to material adjustments from an independent prescription tracking service." (Note that they don't use independent tracking service numbers - presumably Symphony and IMS)."
This is just an example - please do your own due diligence. I can't draw definitive conclusions from this, although I am encouraged.
Agree completely. He should not be speaking for the company. I'm sure he's a nice man but he tends to appear negative (this time and in the past) when it wasn't called for. I am very frustrated with him. I have defended management in the past but this was just not a smart way to put things. He has no PR skills.
Poor choice of words by Matt. Correcting implies there's something wrong and I'm not sure that's the case. He said there are well-known and understood reasons for the "slow start" - I would assume implying that the soft launch was the reason. I don't know, but this hasn't been pretty.
Quite honestly I don't know what to assume. Sanofi reports 1 million euros for essentially two months of sales since the launch was in February. I don't know how things work with prescription drugs, but in the consumer products categories I worked in, sales to retailers like CVS, Walmart and Target are recognized as revenue. It is not sales to the end consumer (equivalent to scripts). Consumer sales are measured using Nielsen data - which is similar to script data. You can not tie Nielsen sales to what you see in you P&L since Nielsen data is based on a "representative sample" of stores. Like scripts, some key retailers like WalMart are not included in the sample. Nielsen data is best to give you a sense of market share and whether sales were trending up or down. In my opinion Afrezza's first quarter numbers are not yet reflective of the brand's potential just yet since we don't have a full quarter of sales, it was a soft launch, and it takes time for the pipeline to fill. I have to assume the numbers include inventory unless someone who works in the industry can tell us otherwise. Just trying to keep it real. That said, I would prefer to be wrong. Still long.
Who are you kidding - and I am long. It is an insane 25% drop from just seconds prior to the premature earnings release.
You have not been losing. But if you continue to short, you are pressing your luck. Hope you've made enough to cover a VW like squeeze and break even.